Suppr超能文献

一种剂量适合所有人吗?成人长期原发性甲状腺功能减退症中左甲状腺素的替代剂量

Does One Size Fit Everyone? Replacement Dose of Levothyroxine in Long-standing Primary Hypothyroidism in Adults.

作者信息

Singh Rekha

机构信息

Department of Endocrinology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India.

出版信息

Indian J Endocrinol Metab. 2017 May-Jun;21(3):404-409. doi: 10.4103/ijem.IJEM_502_16.

Abstract

OBJECTIVES

The recommended starting dose of levothyroxine (LT4) in primary hypothyroidism is 1.6 μg/kg body weight and is based on presumption of minimal residual thyroid function in autoimmune hypothyroidism. This study aimed at finding the range and determining factors for LT4 dose in long-standing hypothyroidism.

METHODS

A cross-sectional study of individuals with primary autoimmune hypothyroidism on LT4 replacement was done between March 2015 and January 2016. Individuals enrolled were euthyroid based on recent serum thyroid-stimulating hormone. The inclusion criteria included LT4 intake in the morning empty stomach, maintenance of at least 1-h food gap, not on medications known to hamper LT4 absorption within 4 h of dosing, diagnosis of hypothyroidism at least for 1 year, and on a minimum 25 μg LT4. < 0.05 was considered statistically significant.

RESULTS

A total of 346 individuals (290 women and 56 men; 214 premenopausal and 76 postmenopausal women) were enrolled. The mean duration of hypothyroidism and age were 5.7 years and 42.1 years, respectively. The range and mean of absolute LT4 daily dose (ADD), LT4 dose based on body weight (D/W), and LT4 dose based on ideal body weight (D/IBW) were 25-200 μg daily and 77.1 μg, 0.3-2.82 μg/kg and 1.21 μg/kg, and 0.42-3.5 μg/kg and 1.58 μg/kg, respectively. Duration of hypothyroidism was significant predictors of ADD, D/W, and D/IBW. Gender-based difference in ADD and D/IBW was explained by gender difference in anthropometry.

CONCLUSION

Long-standing primary autoimmune hypothyroidism has variable dose requirement of LT4 for achieving euthyroidism and may be dependent on the degree of residual functional thyroid. Duration of hypothyroidism was significant positive predictor for either ADD, D/W, or D/IBW.

摘要

目的

原发性甲状腺功能减退症中左甲状腺素(LT4)的推荐起始剂量为1.6μg/千克体重,该剂量基于自身免疫性甲状腺功能减退症中残余甲状腺功能最低的假设。本研究旨在找出长期甲状腺功能减退症患者LT4剂量的范围并确定相关影响因素。

方法

于2015年3月至2016年1月对接受LT4替代治疗的原发性自身免疫性甲状腺功能减退症患者进行了一项横断面研究。根据近期血清促甲状腺激素水平,纳入的患者甲状腺功能正常。纳入标准包括:早晨空腹服用LT4,保持至少1小时的进食间隔,在给药后4小时内未服用已知会妨碍LT4吸收的药物,甲状腺功能减退症诊断至少1年,且LT4最低剂量为25μg。P<0.05被认为具有统计学意义。

结果

共纳入346例患者(290例女性和56例男性;214例绝经前女性和76例绝经后女性)。甲状腺功能减退症的平均病程和年龄分别为5.7年和42.1岁。每日绝对LT4剂量(ADD)、基于体重的LT4剂量(D/W)和基于理想体重的LT4剂量(D/IBW)的范围及平均值分别为每日25 - 200μg和77.1μg、0.3 - 2.82μg/千克和1.21μg/千克、0.42 - 3.5μg/千克和1.58μg/千克。甲状腺功能减退症的病程是ADD、D/W和D/IBW的显著预测因素。ADD和D/IBW的性别差异可通过人体测量学的性别差异来解释。

结论

长期原发性自身免疫性甲状腺功能减退症患者达到甲状腺功能正常所需的LT4剂量存在差异,可能取决于残余功能性甲状腺的程度。甲状腺功能减退症的病程是ADD、D/W或D/IBW的显著正性预测因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab0e/5434723/4b5bb0ab06e9/IJEM-21-404-g005.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验